Brain atrophy in natalizumab-treated patients: A 3-year follow-up

Multiple Sclerosis

Volumn 21, Issue 6, 2015, Pages 749-756

  Sastre Garriga, J ^a   Tur, C ^a   Pareto, D ^a   Vidal Jordana, A ^a   Auger, C ^a   Rio J ^a   Huerga, E ^a   Tintore M ^a   Rovira, A ^a   Montalban, X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

brain atrophy; brain volume; disability; Multiple sclerosis; natalizumab

Indexed keywords

GADOLINIUM; NATALIZUMAB; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; VOLUMETRY; ATROPHY; BRAIN; DISEASE COURSE; DRUG EFFECTS; MIDDLE AGED; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; TIME;

ADULT; ATROPHY; BRAIN; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS; NATALIZUMAB; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84930521304     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514556300     Document Type: Article

References (36)

1. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: Mechanisms and functional consequences. Curr Opin Neurol. 2001 ; 14: 271-278
2. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006 ; 5: 158-170
3. Raz N, Rodrigue KM. Differential aging of the brain: Patterns, cognitive correlates and modifiers. Neurosci Biobehav Rev. 2006 ; 30: 730-748
4. Fisher E, Lee JC, Nakamura K, et al. Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol. 2008 ; 64: 255-265
5. De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010 ; 74: 1868-1876
6. Perez-Miralles F, Sastre-Garriga J, Tintore M, et al. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler. 2013 ; 19: 1878-1886
7. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain. 1996 ; 119: 2009-2019
8. Sastre-Garriga J, Ingle GT, Rovaris M, et al. Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data. Neurology. 2005 ; 65: 633-635
9. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet. 2009 ; 374: 1503-1511
10. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet. 2007 ; 370: 389-397
11. Rudick RA, Fisher E, Lee JC, et al. Brain atrophy in relapsing multiple sclerosis: Relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler. 2000 ; 6: 365-372
12. Rovaris M, Comi G, Rocca MA, et al. Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications. Brain. 2001 ; 124: 1803-1812
13. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain. 2000 ; 123: 2256-2263
14. Montalban X, Sastre-Garriga J, Tintore M, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler. 2009 ; 15: 1195-1205
15. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007 ; 61: 14-24
16. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: An exploratory, randomized, controlled trial. Neurology. 2003 ; 60: 44-51
17. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet. 2004 ; 364: 1489-1496
18. Zivadinov R, Stosic M, Cox JL, et al. The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol. 2008 ; 255: 61-74
19. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007 ; 68: 1390-1401
20. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 402-415
21. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 387-401
22. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012 ; 366: 1000-1009
23. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet. 2012 ; 380: 1819-1828
24. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet. 2012 ; 380: 1829-1839
25. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008 ; 71: 136-144
26. Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014 ; 75: 43-49
27. Vidal-Jordana A, Sastre-Garriga J, Perez-Miralles F, et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler. 2013 ; 19: 1175-1181
28. Horga A, Castillo J, Rio J, et al. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev Neurol. 2011 ; 52: 321-330
29. Smith SM, De Stefano N, Jenkinson M, et al. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr. 2001 ; 25: 466-475
30. Magraner M, Coret F, Casanova B. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients. Eur J Radiol. 2012 ; 81: 3485-3490
31. Portaccio E, Stromillo ML, Goretti B, et al. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: A prospective, non-randomized pilot study. Eur J Neurol. 2013 ; 20: 986-990
32. Rinaldi F, Calabrese M, Seppi D, et al. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Mult Scler. 2012 ; 18: 1760-1767
33. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002 ; 59: 1412-1420
34. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 ; 338: 278-285
35. Borriello G, Prosperini L, Marinelli F, et al. Observations during an elective interruption of natalizumab treatment: A post-marketing study. Mult Scler. 2011 ; 17: 372-375
36. Vrenken H, Jenkinson M, Horsfield MA, et al. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol. 2013 ; 260: 2458-2471